

# MasterClass in Bladder Cancer 2024

**March 7<sup>th</sup>**

**NEW  
VENUE**

Auditorium Hospital  
Universitario 12 de Octubre,  
Hospital Main Building. Low Level.  
Av. de Córdoba, s/n, Madrid

## Scientific coordinators:

**Dr. Daniel Castellano**

Medical Oncology Department,  
Hospital Universitario 12 de Octubre, Madrid

**Dr. Félix Guerrero**

Urology Department,  
Hospital Universitario 12 de Octubre, Madrid

## Format:

– In person –

**INSCRIPCIONES AQUÍ**

**Organized by:**

**HENDERE HEALTHCARE**



**Hospital Universitario  
12 de Octubre**



March 7<sup>th</sup>, 2024

13:30 - 14:00 **Registration**

14:00 - 14:10 **Welcome and introduction**

Dr. Daniel Castellano, Medical Oncology Department,  
Hospital Universitario 12 de Octubre, Madrid

Dr. Félix Guerrero, Urology Department,  
Hospital Universitario 12 de Octubre, Madrid

Dr. Alfredo Rodríguez, Head of the Urology Department,  
Hospital Universitario 12 de Octubre, Madrid

14:10 - 15:00 **Let's start with molecular biology**

*Moderators:*

Dr. Jesús Paramio, CIEMAT - Hospital Universitario 12 de Octubre, Madrid  
Dr. Francisco X. Real, Grupo Carcinogenesis Epitelial, CNIO, Madrid

14:10 - 14:25 **Urine-based liquid biopsy for bladder cancer monitoring. BlaDimiR and UCIPredict projects**

Dra. Marta Dueñas, CIEMAT - Hospital Universitario 12 de Octubre, Madrid

14:25 - 14:40 **Molecular landscape in NMIBC**

**ONLINE** Dr. Bishoy M. Faltas, Genitourinary Oncology Program in the Division of Hematology & Medical Oncology. Weill Cornell Medical College, New York. USA

14:40 - 15:00 **Discussion**

15:00 - 16:15 **Non muscle-invasive bladder cancer**

*Moderators:*

Dr. Mario Álvarez, Urology Department, Hospital Universitario La Paz, Madrid  
Dr. José Luis Domínguez, Urology Department,  
Instituto Valenciano de Oncología, Valencia

15:00 - 15:15 **Biomarkers for the diagnosis/surveillance of NMIBC**

Dr. Fernando Lozano, Urology Department,  
Hospital Universitari Vall d'Hebron, Barcelona

15:15 - 15:30 **Artificial intelligence for NMIBC risk stratification**

Dr. José Daniel Subiela, Urology Department,  
Hospital Universitario Ramón y Cajal, Madrid

15:30 - 15:45 **Intravesical alternatives for BCG unresponsive NMIBC**

Dr. Félix Guerrero, Urology Department,  
Hospital Universitario 12 de Octubre, Madrid

15:45 - 16:00 **The future of systemic therapy in NMIBC: what, when and how?**

**ONLINE** Dr. Bernadett Szabados, Urology Department,  
Barts Cancer Institute, London

16:00 - 16:15 **Discussion**



March 7<sup>th</sup>, 2024

16:15 - 17:30

## Muscle-invasive bladder cancer

### *Moderators:*

**Dr. José Rubio**, Urology Department, Hospital Vithas Valencia 9 de Octubre

**Dr. Ignacio Durán**, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

16:15 - 16:30

## Updating New systemic treatment strategies for bladder preservation

**ONLINE** **Dr. Matthew Galsky**, Genitourinary Medical Oncology, Mount Sinai Medical Center, New York, USA

16:30 - 16:45

## Minimally invasive surgery for MIBC: present and future

**Dr. Rafael Medina**, Urology Department, Hospital Universitario Virgen del Rocío, Sevilla

16:45 - 17:00

## Current situation of bladder preservation approaches for MIBC: trimodal therapy and beyond

**Dr. Óscar Rodríguez**, Urology Department, Fundació Puigvert, Barcelona

17:00 - 17:15

## Adjuvant therapy: to whom and how

**Dr. Teresa Alonso**, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid

17:15 - 17:30

## Discussion

17:30 - 18:00

## Coffee break

18:00 - 19:00

## Advanced bladder cancer

### *Moderators:*

**Dr. Javier Puente**, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

**Dr. Guillermo de Velasco**, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

18:00 - 18:15

## Current landscape of first line therapy for mUC

**Dr. Daniel Castellano**, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

18:15 - 18:30

## Current landscape of second/third line therapy for mUC

**Dr. María José Juan Fita**, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

18:30 - 18:45

## Biomarkers for mUrothelial Carcinoma. (nectin-4, Trop-2, HER2, FGFR)

**ONLINE** **Dr. Vadim S. Koshkin**, Division of Hematology/Oncology, Department of Medicine University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

18:45 - 19:00

## Discussion

19:00 - 19:10

## Conclusions and farewell

**Dr. Daniel Castellano**, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

**Dr. Félix Guerrero**, Urology Department, Hospital Universitario 12 de Octubre, Madrid

## SPONSORS



Johnson & Johnson

MERCK



AstraZeneca

Bristol Myers Squibb

Palex  
Constant Improvement

Under the auspice of



Actividad solicitada al Consejo Catalán de Formación Continuada de las Profesiones Sanitarias - Comisión de Formación Continuada del Sistema Nacional de Salud" para las profesiones: Médicos especialistas en Oncología Médica

SECRETARÍA TÉCNICA:

tactics  
20 years working together

Passatge Batlló 15, 08036 Barcelona

93 451 17 24

info@tacticsmd.net

www.tacticsmd.net